Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermDebt,accountsPayable,otherCurrentLiab,otherCurrentAssets,netReceivables,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,otherCashflowsFromInvestingActivities,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,marketState,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GMDA,83897000.0,59200200,11366000,,-18486000,,-18039000,7843000,0,-19209000,-19209000,,-664000,,,,-447000,0,19209000,0,723000,,-18039000,-18039000,378478000.0,122107000.0,83897000.0,206004000.0,167000.0,-294307000.0,28606000.0,-441000.0,772000.0,174798000.0,19867000.0,-441000.0,27082000.0,178150000.0,68646000.0,7204000.0,,,,875000.0,-2806000.0,70348000.0,70434000.0,-3247000.0,502000.0,47628000.0,34000.0,-20034000.0,635000.0,-416000.0,-258000.0,-2806000.0,,,158283000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,4.5,1630526402,-0.03999996,4.53,4.65,4.46,431485,-2.4465218,-0.35219377,266400896,-3.0,3.2188842,15,America/New_York,EDT,-14400000,False,False,USD,4,Gamida Cell Ltd.,NGM,-1.57,-2.866242,1.398,5.2414284,-0.7414284,-0.14145541,6.9465218,0,finmb_556352,NasdaqGM,Gamida Cell Ltd.,USD,487162,610057,0.5,0.125,4.0 - 15.0,-10.5,-0.7,4.0,15.0,1620736200,1636378200,1636551000,-1.594,-1.5,PREPRE,0.0,1630526402,4.5,0.0,-0.88105637,4.46 - 4.65,4.54,0.0,0.0,8,8,us_market,1.91,,,15.0,4.0,5.2414,6.9465,487.16k,610.06k,59.2M,,41.63M,28.15%,47.60%,1.84M,5.64,3.73%,3.11%,2.09M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-32.88%,-146.81%,,,,,-68.73M,-80.14M,-1.5940,,174.8M,2.91,75.71M,90.24,8.97,1.40,-56.34M,-43.49M,Value,91340,Healthcare,110,"Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.",Jerusalem,972 2 659 5666,1609372800,Israel,http://www.gamida-cell.com,86400,5 Nahum Heftsadie Street,Biotechnology,Givaat Shaul
t-1,GMDA,98737000.0,59200200,13733000,,-32295000,,-32295000,8322000,0,-22055000,-22055000,,-1967000,,,,0,0,22055000,0,-10240000,,-32295000,-32295000,375280000.0,56746000.0,98737000.0,155483000.0,166000.0,-276268000.0,29814000.0,-441000.0,786000.0,127170000.0,21554000.0,-441000.0,24712000.0,129985000.0,,6329000.0,1204000.0,152000.0,103000.0,3548000.0,-2170000.0,-446000.0,69690000.0,3656000.0,69937000.0,53859000.0,-93000.0,-13568000.0,681000.0,199000.0,12468000.0,-2012000.0,-158000.0,-1626000.0,108431000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,4.5,1630526402,-0.03999996,4.53,4.65,4.46,431485,-2.4465218,-0.35219377,266400896,-3.0,3.2188842,15,America/New_York,EDT,-14400000,False,False,USD,4,Gamida Cell Ltd.,NGM,-1.57,-2.866242,1.398,5.2414284,-0.7414284,-0.14145541,6.9465218,0,finmb_556352,NasdaqGM,Gamida Cell Ltd.,USD,487162,610057,0.5,0.125,4.0 - 15.0,-10.5,-0.7,4.0,15.0,1620736200,1636378200,1636551000,-1.594,-1.5,PREPRE,0.0,1630526402,4.5,0.0,-0.88105637,4.46 - 4.65,4.54,0.0,0.0,8,8,us_market,1.91,,,15.0,4.0,5.2414,6.9465,487.16k,610.06k,59.2M,,41.63M,28.15%,47.60%,1.84M,5.64,3.73%,3.11%,2.09M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-32.88%,-146.81%,,,,,-68.73M,-80.14M,-1.5940,,174.8M,2.91,75.71M,90.24,8.97,1.40,-56.34M,-43.49M,Value,91340,Healthcare,110,"Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.",Jerusalem,972 2 659 5666,1609372800,Israel,http://www.gamida-cell.com,86400,5 Nahum Heftsadie Street,Biotechnology,Givaat Shaul
t-2,GMDA,60568000.0,59200200,10454000,,-14752000,,-14752000,4606000,0,-15060000,-15060000,,-1001000,,,,0,0,15060000,0,308000,,-14752000,-14752000,304944000.0,38140000.0,60568000.0,98708000.0,138000.0,-243973000.0,18754000.0,-541000.0,802000.0,73311000.0,13926000.0,-541000.0,22861000.0,75045000.0,,2704000.0,,,,-39000.0,-2683000.0,-417000.0,-396000.0,1488000.0,21000.0,-15327000.0,31000.0,-12279000.0,610000.0,199000.0,414000.0,-2683000.0,-158000.0,-1626000.0,61119000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,4.5,1630526402,-0.03999996,4.53,4.65,4.46,431485,-2.4465218,-0.35219377,266400896,-3.0,3.2188842,15,America/New_York,EDT,-14400000,False,False,USD,4,Gamida Cell Ltd.,NGM,-1.57,-2.866242,1.398,5.2414284,-0.7414284,-0.14145541,6.9465218,0,finmb_556352,NasdaqGM,Gamida Cell Ltd.,USD,487162,610057,0.5,0.125,4.0 - 15.0,-10.5,-0.7,4.0,15.0,1620736200,1636378200,1636551000,-1.594,-1.5,PREPRE,0.0,1630526402,4.5,0.0,-0.88105637,4.46 - 4.65,4.54,0.0,0.0,8,8,us_market,1.91,,,15.0,4.0,5.2414,6.9465,487.16k,610.06k,59.2M,,41.63M,28.15%,47.60%,1.84M,5.64,3.73%,3.11%,2.09M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-32.88%,-146.81%,,,,,-68.73M,-80.14M,-1.5940,,174.8M,2.91,75.71M,90.24,8.97,1.40,-56.34M,-43.49M,Value,91340,Healthcare,110,"Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.",Jerusalem,972 2 659 5666,1609372800,Israel,http://www.gamida-cell.com,86400,5 Nahum Heftsadie Street,Biotechnology,Givaat Shaul
t-3,GMDA,74550000.0,59200200,9319000,,-15055000,,-15055000,3525000,0,-12844000,-12844000,,-2320000,,,,0,0,12844000,0,-2211000,,-15055000,-14875000,304175000.0,38665000.0,74550000.0,113215000.0,137000.0,-229221000.0,19140000.0,-541000.0,642000.0,88638000.0,13579000.0,-541000.0,21694000.0,90879000.0,,2738000.0,,,,-360000.0,-4990000.0,-335000.0,63813000.0,1865000.0,64001000.0,48346000.0,-24000.0,-10453000.0,556000.0,147000.0,2541000.0,-4990000.0,-158000.0,-1626000.0,77300000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,4.5,1630526402,-0.03999996,4.53,4.65,4.46,431485,-2.4465218,-0.35219377,266400896,-3.0,3.2188842,15,America/New_York,EDT,-14400000,False,False,USD,4,Gamida Cell Ltd.,NGM,-1.57,-2.866242,1.398,5.2414284,-0.7414284,-0.14145541,6.9465218,0,finmb_556352,NasdaqGM,Gamida Cell Ltd.,USD,487162,610057,0.5,0.125,4.0 - 15.0,-10.5,-0.7,4.0,15.0,1620736200,1636378200,1636551000,-1.594,-1.5,PREPRE,0.0,1630526402,4.5,0.0,-0.88105637,4.46 - 4.65,4.54,0.0,0.0,8,8,us_market,1.91,,,15.0,4.0,5.2414,6.9465,487.16k,610.06k,59.2M,,41.63M,28.15%,47.60%,1.84M,5.64,3.73%,3.11%,2.09M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-32.88%,-146.81%,,,,,-68.73M,-80.14M,-1.5940,,174.8M,2.91,75.71M,90.24,8.97,1.40,-56.34M,-43.49M,Value,91340,Healthcare,110,"Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.",Jerusalem,972 2 659 5666,1609372800,Israel,http://www.gamida-cell.com,86400,5 Nahum Heftsadie Street,Biotechnology,Givaat Shaul
